Seeking Alpha

Isis Pharmaceuticals (ISIS -8%) gets hit after its Q3 report falls wide of the mark. Revenue...

Isis Pharmaceuticals (ISIS -8%) gets hit after its Q3 report falls wide of the mark. Revenue plummeted 43% Y/Y due to the volatility of its income stream, which largely consists of licensing fees, milestone payments and other similar billing arrangements.

Check out Seeking Alpha’s new Earnings Center »

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs